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ABSTRACT
A 48-year-old female, who was found
unresponsive and suffered inhalation injury
secondary to a house fire, was transferred to
our burn center for definitive treatment. Post
tracheostomy, the patient became febrile and
tachycardic. On hospital day (HD) 5, the patient
expressed thick yellow secretions during
suctioning and diffuse rhonchi was noted on
physical exam. Blood cultures and a culture
from the broncheo-alvelolar lavage grew
Gram-positive cocci in clusters and the patient
was started on empiric vancomycin. Despite
aggressive vancomycin dosing (1750 mg
intravenously every 6 h), the patient’s status
continued to deteriorate. The organism was
identified as methicillin-resistant Staphylococcus
aureus (MRSA) with a vancomycin minimum
inhibitory concentration (MIC) of 2 mg/L.
Based on the potential for drug–drug
interactions with linezolid, the patient was
started on ceftaroline fosamil (MIC = 0.5 mg/
L) 600 mg intravenously every 8 h with a
prolonged 2-h infusion to anticipate
suboptimal concentrations secondary to
thermal burn injury. Post change in antibiotic
therapy, a rapid clinical improvement was
observed with the patient becoming afebrile at
48 h after initiation of ceftaroline. The patient
completed a total of 14 days of ceftaroline
therapy and was subsequently weaned from
the ventilator on HD 22 and decannulated
2 days later. To our knowledge, this is the first
report of the use of ceftaroline for the treatment
of MRSA pneumonia in a patient with thermal
injury.
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Infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) are a frequent
occurrence in most medical centers, especially
in patients admitted to the intensive care unit
(ICU) for prolonged periods of time. These
infections can be secondary to implanted
catheters, skin and soft tissue infections, and
pneumonia. Patients with extensive thermal
injuries are at high risk of developing
infections from MRSA and other
multi-drug-resistant pathogens due to their
need for prolonged ICU care, frequent receipt
of antimicrobial therapy, and the
immunological and physiological disturbances
encountered as a result of their injuries.
Historically vancomycin, a glycopeptide
antimicrobial, has been the treatment of
choice for MRSA infections. However, the
clinical utility of vancomycin has recently
been questioned when employed in the
treatment of MRSA infections when the mean
inhibitory concentration (MIC) of vancomycin
is greater than 1 mg/L, with published literature
reporting increased treatment failure and
mortality in patients due to inability to attain
currently established pharmacokinetic (PK) and
pharmacodynamic (PD) targets [1–3].
Ceftaroline fosamil (Teflaro; Actavis
Pharmaceuticals), an advanced cephalosporin
with activity against MRSA, was approved by
the Food and Drug Administration (FDA) for the
treatment of acute bacterial skin and skin
structure infections and community-acquired
bacterial pneumonia (CABP). We describe a case
of MRSA pneumonia in a patient with
inhalational thermal injuries who did not
respond to initial vancomycin therapy
(vancomycin MIC = 2 mg/L) but responded
clinically to treatment with ceftaroline.
Currently, there are limited data available to
support the utilization of ceftaroline for the
treatment of pneumonia caused by MRSA.
There are no data that we are aware of with
respect to treatment of patients with
burn-related infections. This article does not
contain any new studies with human or animal
subjects performed by any of the authors.
CASE REPORT
A 48-year-old Caucasian female was found
unresponsive at the scene of a house fire with
burns to the face [\1% total body surface area
(BSA)] and inhalation injury. She was intubated
via endotracheal tube at an outside facility and
subsequently transferred to our burn center for
definitive care. The initial bronchoscopy
showed diffuse carbonaceous sputum with
pale friable mucosa extending throughout the
airways distally. The patient was intubated for
airway protection, which required adequate
sedation and neuromuscular blockade. Due to
the inability of the patient to provide a detailed
medical history, the patient’s sister and
psychiatrist supplied the relevant information,
which included a diagnosis of severe depression
with psychotic features. On admission, the
patient’s list of home medications included
paliperidone palmitate 234 mg once monthly
as an intramuscular injection, paliperidone
6 mg by mouth daily, citalopram 40 mg by
mouth daily, trazodone 150 mg by mouth at
bedtime, risperidone 2 mg by mouth twice
daily, and clonazepam 1 mg by mouth twice
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daily. The patient had no known drug allergies
or other relevant medical history. She was a
chronic smoker and substance abuser, but on
admission the urine drug screen was negative.
Upon admission to the burn ICU, the patient
had a mild leukocytosis (white blood cell count
15.8 k/mm3) but was afebrile, normotensive, and
demonstrated adequate urine output ([0.5 mL/
kg/hr). She had evidence of acute respiratory
distress syndrome (ARDS), with a ratio of partial
pressure arterial oxygen and fraction of inspired
oxygen of less than 200, and was started on
pressure control ventilation. Due to the severity
of the inhalation injury and the need for
prolonged mechanical ventilation with
aggressive pulmonary hygiene, a tracheostomy
was performed on the second hospital day (HD).
Post-operatively, the patient became febrile with
an associated tachycardia. By HD 5, the patient
expressed thick yellow secretions during
suctioning and on physical examination diffuse
rhonchi were appreciated, worse in the right lung
than the left, corresponding with a worsening
right-sided, patchy infiltrate seen on chest X-ray.
A culture from the broncheo-alvelolar lavage
(BAL) on HD 6 revealed gram-positive cocci in
clusters (Table 1). Blood cultures obtained on HD
4 also grew Gram-positive cocci in clusters, and
the patient was started on empiric vancomycin
and cefepime on HD 6 for presumed
Table 1 Cultures and susceptibilities of select antibiotics
Date Site Organism Susceptibility (mg/L)
HD 4 Blood MRSA Daptomycin: MIC\0.5
Gentamicin: MIC\4
TMP/SMX: MIC\0.5/9.5
Vancomycin: MIC = 1
HD 4 Respiratory MRSA Gentamicin: MIC\0.5
Linezolid: MIC\4
TMP/SMX: MIC\0.5/9.5
Vancomycin: MIC = 1
HD 6 Quantitative BAL [180,000 CFU/mL MRSA Gentamicin: MIC\4
Linezolid: MIC\4
TMP/SMX: MIC\0.5/9.5
Vancomycin: MIC = 2
Ceftaroline: MIC = 0.5
HD 10 Quantitative BAL [110,000 CFU/mL MRSA Gentamicin: MIC\4
Linezolid: MIC\4
TMP/SMX: MIC\0.5/9.5
Vancomycin: MIC = 2
HD 10 Blood No growth
BAL broncheo-alvelolar lavage, CFU colony forming units, HD hospital day, MIC mean inhibitory concentration, MRSA
methicillin-resistant Staphylococcus aureus, TMP/SMX trimethoprim/sulfamethoxazole
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hospital-acquired pneumonia with associated
bacteremia. However, despite an aggressive
vancomycin dosing schedule [1750 mg
intravenous (IV) every 6 h] and adequate,
supratherapeutic, vancomycin trough
concentrations of 26 mg/L, the patient’s clinical
status did not improve. She continued to be
febrile and tachycardic, requiring increased
ventilatory support and oxygenation
requirements. Repeat urine and blood cultures
obtained on HD 5 were negative for the
Gram-positive pathogen, which was at this time
identified as MRSA. The repeat bronchoscopy on
HD 10 demonstrated mild improvement in
secretions, but the Gram-stain from the BAL
subsequently yielded growth in culture of
[110,000 colony forming units/mL
gram-positive cocci in clusters, later identified as
MRSA with a vancomycin MIC of 2 mg/L by
automated susceptibility testing. Due to the
patient’s deteriorating clinical status on HD 10
while on high-dose vancomycin therapy, the
decision was made to modify the antibiotic
regimen. At the Detroit Medical Center, in
accordance with suggested treatment pathways,
MRSA bacteremia and/or pneumonia and a
vancomycin MIC of C2 mg/L constitute a reason
to change therapy to a suitable alternative.
However, with consideration of the patient’s
medication history, and current medication
regimen of antipsychotics and a selective
serotonin reuptake inhibitor (SSRI), linezolid was
not employed due to the possibility of drug–drug
interactions with the psychiatric medications.
After consultation with the infectious diseases
(ID) pharmacist and the ID medical consult
service, a decision was made to initiate
ceftaroline fosamil (Teflaro) for the treatment of
this patient’s MRSA pneumonia.
Ceftaroline fosamil (Teflaro) is a new
advanced generation cephalosporin approved
by the FDA for use in acute bacterial skin and
skin structure infection (ABSSSI) including
MRSA and CABP caused by susceptible
bacteria. Ceftaroline binds to the
penicillin-binding proteins including PBP 2a
associated with methicillin resistance in S.
aureus and prevents the cross-linkage of
peptidoglycan in bacterial cell walls [4–6].
Ceftaroline fosamil, a prodrug, is converted to
the active form of ceftaroline via serum
phosphatases and undergoes minimal
cytochrome P450 oxidation. Approximately
88% of a dose of ceftaroline is excreted
renally, with only 6% of the drug recovered in
the feces [4]. The prescribing information
indicates the approved dose of ceftaroline
fosamil administered intravenously is 600 mg
every 12 h for ABSSSI and CABP [7]. However,
due to the increased volume of distribution
(Vd), renal clearance, and urine output in burn
injury patients, the patient’s regimen was
empirically modified to 600 mg IV every 8 h,
and administered as a 2-h infusion to ensure
that adequate drug concentrations be
maintained throughout the dosing interval.
The clinical MRSA isolate tested had a
ceftaroline MIC of 0.5 mg/L by Etest
(bioMe´rieux SA). This antimicrobial regimen
was continued for a total of 14 days. The patient
became afebrile 48 h after initiation of
ceftaroline and remained afebrile for the
length of the hospital stay. Rapid clinical
improvement was seen after initiation of
ceftaroline; the patient was subsequently
weaned from the ventilator on HD 22 and
decannulated 2 days later. However, because of
her psychiatric illness and auditory/visual
hallucinations, hospital discharge was delayed
to allow for psychiatric placement.
Due to the relative lack of clinical data
supporting the use of ceftaroline in burn
patients, serum concentrations of ceftaroline
were obtained for PK characterization and
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potential dosage adjustment. Serum drug levels
were obtained on day five of ceftaroline
therapy. Concentrations were obtained 30 min
post-infusion, 2 h later, and a final
concentration drawn 30 min prior to the next
dose (Table 2).
Serum Drug Assay and PK
Characterization
The ceftaroline bioassay was performed
according to previously published methods [8].
Briefly, quarter-inch disks were placed on agar
plates (antibiotic medium number 11)
pre-swabbed with Bacillus subtilis ATCC 6633.
The disks were spotted with 10 lL of ceftaroline
standards (2.5, 10, and 40 mg/L) or plasma
samples. Each standard and sample was tested
in duplicate. Plates were incubated for 18–24 h
at 37 C, after which the zone sizes were
measured using a protocol reader (Protocol;
Microbiology International, Frederick, MD,
USA). Ceftaroline half-life, Cmax (peak), and
Cmin (trough) mg/L were determined from
concentration-versus-time plots assuming a
one-compartment model (Table 2).
Patient-specific concentrations and time above
MIC (T[MIC) were calculated utilizing
first-order elimination concepts (Table 3). The
elimination half-life, peak and trough
concentrations, and area under the curve
(AUC) were calculated using PK Analyst
Software (version 1.10; MicroMath Scientific
Software, Salt Lake City, UT, USA).
DISCUSSION
MRSA is a frequently encountered pathogen in
burn units and poses a serious health risk. As
aforementioned, this risk is not limited to burn
site infections but can be associated with
bacteremia and pneumonia. Due to the
severity of burn injuries, patients may require
multiple surgical procedures, numerous
invasive central catheters, and prolonged
periods of mechanical ventilation. These risk
factors, in addition to the decreased
immunological response, can dramatically
increase the mortality rates in burn patients.
Treatment of these infections in this patient
population can present a PK challenge for
clinicians, and patients frequently require high
Table 2 Patient-speciﬁc ceftaroline levels
Time Ceftaroline level (mg/L)





a 30 min post-infusion











Burn patient 27.5 1.69 1.5 0.42 87.6 8 10
Package insert 21.3 2.3–2.9 0.31–0.45 56.3 9.6
It should be noted that the AUC0–s for the burn patient is for 0–8 and 0–12 h per the package insert (i.e., the dosing
interval)
AUC area under the curve, Cmax maximum serum concentration, Cmin minimum serum concentration, MIC mean
inhibitory concentration, T half-life, Vd volume of distribution
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doses of antimicrobials to maintain adequate
serum concentrations [9–14].
Patients that suffer from a thermal injury
have numerous pathophysiological changes,
which can dramatically alter the PK/PD of
prescribed medications. The physiological
changes vary based on the time elapsed from
the initial burn injury. The acute phase occurs
within the first 72 h of the burn injury and
results in decreased cardiac and urine output,
and increased systemic vascular resistance,
which can affect the distribution and
elimination of medications [15]. These
alterations in cardiac output, renal clearance,
and protein binding can significantly alter the
PK properties of most medications including
absorption, distribution, and elimination [15,
16]. The hypermetabolic phase occurs around
72 h after the burn injury. During this second
phase of burn injury, patients will have
increased levels of catecholamines,
prostaglandins, glucagon, and cortisol which
result in increased cardiac output and
glomerular filtration rates [15]. Decreased
albumin and increased acute-phase proteins
resulting from the acute injury can also
potentially alter the effectiveness of highly
protein bound drug molecules since only free
drug is available to elicit an effect [15, 16].
Additionally, the Vd in significantly burned
patients ([20% total BSA), or patients with an
inhalation injury, can be altered due to
extensive fluid loss from the burned tissue
[16]. Finally, hepatic metabolism of
medications varies after a burn injury [12, 13,
15, 16]. In the hypermetabolic phase, a decrease
in phase 1 metabolism can increase the half-life
of medications that are hepatically metabolized
and cleared, which ultimately increases the risk
of toxicity to the patient. However, phase 2
metabolism, or glucuronidation, does not
appear to be affected during the
hypermetabolic phase of burn injury [17].
Alterations in the physiological response to a
burn make dosing medications, especially
antibiotics, challenging in burn patients.
Although not typically discussed in burn
literature, an inhalation injury elicits the same
physiological response as any other thermal
injury [18]. Lovering and colleagues [19]
evaluated the dosing regimens of linezolid in
patients with [20% total BSA. In their study,
the burn patients had increased non-renal
clearance of the drug and elimination rate
constants. However, the Cmax concentrations
and the Vd of linezolid were similar between the
burn patients and healthy volunteers. A case
report of a 27-year-old male with a 52% total
BSA burn demonstrated that the typical dose of
linezolid 600 mg IV every 12 h and meropenem
1 g IV every 8 h produced subtherapeutic serum
concentrations in the patient, necessitating an
increase in the frequency of dosing to obtain
adequate concentrations of the antibiotics in
serum, including T[MIC [20]. Daptomycin
Cmax concentrations and AUC values have also
been reported to be less (44% and 47%,
respectively) in patients with thermal injury,
with these patients experiencing a 77% increase
in mean clearance values compared to healthy
volunteers [12]. This study found that
daptomycin doses would need to be increased
to 10–12 mg/kg/dose to approximate drug
exposures in healthy volunteers (dosed at
6 mg/kg/dose). Overall, the alterations in PK
parameters in these antibiotics are variable
based on burn size and renal function [16, 21].
In one study evaluating cefepime, the renal
clearance and Vd were reportedly 10–30%
higher in burn patients than non-burn
patients [9]. As a result of available data in
burn patients, the practice of increasing the
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dose, as well as the frequency of administration,
may be reasonable to maintain therapeutic
serum concentrations of antibiotics [9, 20, 21].
In this case, alternative antimicrobial therapy
was sought due to the patient’s lack of clinical
response to vancomycin therapy coupled with an
elevatedvancomycinMIC (2 mg/L).Aspreviously
mentioned, although literature supports linezolid
in the treatmentofnosocomialpneumonia, itwas
notchosendueto thepotential for subtherapeutic
concentrations resulting from
pathophysiological changes. In addition, due to
the patient’s medication history, there was a
potential for drug–drug interactions with the
patient’s prescribed antipsychotic medication,
which included an SSRI and linezolid. Case
reports have cautioned against the use of this
combination as near-fatal serotonin syndrome
has been reported with linezolid’s inhibition of
MAO-A and B [22]. Therefore, ceftaroline was
initiated using the 600 mg dose at an 8-h dosing
schedule, administered as a 2-h infusion, to
maximize the PK/PD of the cephalosporin class
(i.e., time-dependent killing) and allowing for
infusion of other IVmedications simultaneously.
This dosing regimen has been studied in
in vitro PK/PD models and shown to be highly
effective against MRSA, while the 12-h regimen
has been studied in complicated skin and skin
structure infections and for treatment of CABP
[23–27]. Bhavnani et al. [28] used Monte Carlo
Simulation (MCS) to simulate 2000 patient
exposures with the 600 mg IV every 12 h dose,
evaluating the ability of this dosing regimen to
attain a free drug time above the MIC
(f%T[MIC) target up to 51% of the dosing
interval against S. aureus isolates, utilizing a wide
range of MICs (0.125–16 mg/L). Interestingly,
against simulated isolates with MICs typically
seen at this institution based upon internal data
(MIC90 1 mg/L), it was reported that 600 mg IV
every 12 h would only achieve this PD endpoint
in 76.2% of the simulated patients with normal
renal function [28]. Recently, a published report
where 600 mg IV every 8 h was initiated in 5 out
of 6 patients with S. aureus bacteremia (3
endocarditis, 1 urinary tract infection, 1
ethmoid osteomyelitis with uveitis, and 1
prostatitis with septic thrombophlebitis)
demonstrated resolution of infection in 5 out
of the 6 patients, including one patient with a
vancomycin-intermediate (vancomycin
MIC= 4 mg/L) isolate [29]. Recently, Casapao
and colleagues [30] described 527 patients who
received ceftaroline therapy, including 241
patients infected with MRSA. In this
observational study of patients who received
ceftaroline for various indications, 76 (14.4%)
received an off-label dose. Side effects were noted
to be slightly higher in these patients (17.1%)
but all side effects reported in this study were
noted to be B7.8% [30]. Although most patients
in these reports received multiple agents active
against MRSA, the results support further
research into the efficacy and safety of
ceftaroline at this increased dose. Extended
infusion beta-lactam therapy has shown
promise in the treatment of ICU infections,
notably with piperacillin/tazobactam (given as
a 4-h infusion) [31]. Infusion times longer than
2 h were not feasible in this patient due to a
combination of drug stability (manufacturer
labeling indicates 6-h stability at room
temperature) and shortage of infusion sites
from demand for other non-antimicrobial
parenteral infusions.
Serum concentrations (obtained to
characterize the pathophysiological changes
associated with inhalational thermal injuries)
demonstrated that serum drug concentrations
remained above the MIC (0.5 mg/L by Etest) for
the full duration of the dosing interval. The 8-h
dosing regimen was continued due to the
potential for increased drug clearance noted in
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this patient, as the high inoculum infection,
which could impact the efficacy of ceftaroline.
This ‘‘inoculum effect’’ has been noted with
other beta-lactams, including cephalosporins as
well as glycopeptide antimicrobials [32–34]. Our
patient demonstrated similar drug clearance
and Vd compared to healthy adults. However,
this patient also demonstrated a much shorter
half-life (1.5 versus 2.66 h) and increased AUC
(87.6 versus 56.3 lg h/mL), when compared
with data reported in the ceftaroline
prescribing information. This finding was
dissimilar to previously published reports
characterizing the increased clearance of
beta-lactam antimicrobials in patients with
thermal injury [9, 11, 14]. This could
potentially be due to the limited amount of
burn injury (\1% total BSA) and time period
from the burn injury itself, as the ceftaroline
therapy was initiated in this patient many days
into their admission. Curiously, the
concentration obtained 30-min post-infusion
was higher than reported in the prescribing
information and cannot be completely
explained other than this patient exhibited
altered ceftaroline PK distribution. The patient
completed a total of 14 days of ceftaroline
therapy and responded appropriately with
resolution of signs and symptoms of infection,
and more importantly with no reported toxicity
from antimicrobial therapy. Ultimately, the
patient was liberated from mechanical
ventilation on HD 22 and discharged to a
psychiatric care facility on HD 48.
CONCLUSION
In conclusion, we describe a case of an
inhalational thermal burn injury patient
successfully treated with ceftaroline 600 mg IV
every 8 h for documented MRSA pneumonia
with a vancomycin MIC of 2 mg/L. We also
characterized the PK of ceftaroline in a patient
with inhalational thermal injuries utilizing a
higher than normal dose of medication with
the aim of optimizing serum concentrations
due to their disease pathophysiology. Our
patient demonstrated higher calculated AUC
values resulting from the higher dose and
increased frequency of dosing, as well as
shorter serum half-life. Larger studies are
needed to further evaluate this increased dose
for safety and efficacy. Clinicians should
recognize these pathophysiological changes in
burn injury patients and, if possible, adjust
treatment accordingly, thus allowing for
improved patient outcomes.
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